{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:04:34Z","timestamp":1789387474983,"version":"build-2803163510"},"reference-count":237,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008637","name":"National Cancer Institute Center for Strategic Scientific Initiatives","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stress and Chaperones"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cstres.2026.100193","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:52:09Z","timestamp":1781851929000},"page":"100193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of Hsp90 targeting: From stress biology to clinical translation"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-3009","authenticated-orcid":false,"given":"Ilham","family":"Zarguan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamiae","family":"Belayachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Benjouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-9694","authenticated-orcid":false,"given":"Ahmed","family":"Chadli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.cstres.2026.100193_bib1","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0092-8674(00)80314-1","article-title":"Identification and structural characterization of the ATP\/ADP-binding site in the Hsp90 molecular chaperone","volume":"90","author":"Prodromou","year":"1997","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(00)80203-2","article-title":"Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent","volume":"89","author":"Stebbins","year":"1997","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/sj.emboj.7600141","article-title":"Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery - PubMed","volume":"23","author":"Meyer","year":"2004","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2015.06.018","article-title":"Regulation and function of the human HSP90AA1 gene - PubMed","volume":"570","author":"Zuehlke","year":"2015","journal-title":"Gene"},{"issue":"7625","key":"10.1016\/j.cstres.2026.100193_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nature19807","article-title":"The epichaperome is an integrated chaperome network that facilitates tumour survival","volume":"538","author":"Rodina","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.09.007","article-title":"Paradigms for precision medicine in epichaperome cancer therapy - PubMed","volume":"36","author":"Pillarsetty","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Neckers","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.cstres.2026.100193_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: emerging mechanistic insights","volume":"11","author":"Taipale","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib10","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1038\/24550","article-title":"Hsp90 as a capacitor for morphological evolution","volume":"396","author":"Rutherford","year":"1998","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41580-023-00640-9","article-title":"Structural and functional complexity of HSP90 in cellular homeostasis and disease - PubMed","volume":"24","author":"Chiosis","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/BF02172188","article-title":"A new puffing pattern induced by temperature shock and DNP in drosophila","volume":"18","author":"Ritossa","year":"1962","journal-title":"Experientia"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0022-2836(74)90447-1","article-title":"Protein synthesis in salivary glands of Drosophila melanogaster: relation to chromosome puffs","volume":"84","author":"Tissi\u00e8res","year":"1974","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib14","first-page":"3","article-title":"Localization of RNA from heat-induced polysomes at puff sites in Drosophila melanogaster","volume":"72","author":"McKenzie","year":"1975"},{"issue":"997","key":"10.1016\/j.cstres.2026.100193_bib15","article-title":"Heat shock of Drosophila melanogaster induces the synthesis of new messenger RNAs and proteins","volume":"283","author":"Moran","year":"1978","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.78.2.1067","article-title":"A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein - PubMed","volume":"78","author":"Oppermann","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/0092-8674(81)90055-6","article-title":"The specific interaction of the Rous sarcoma virus transforming protein, pp60src, with two cellular proteins","volume":"25","author":"Brugge","year":"1981","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib18","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/S0021-9258(18)33075-8","article-title":"Identification and expression of a cloned yeast heat shock gene","volume":"258","author":"Finkelstein","year":"1983","journal-title":"J Biol Chem"},{"issue":"26","key":"10.1016\/j.cstres.2026.100193_bib19","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1016\/S0021-9258(17)38716-1","article-title":"A 90,000-dalton binding protein common to both steroid receptors and the Rous sarcoma virus transforming protein, pp60v-src","volume":"260","author":"Schuh","year":"1985","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.cstres.2026.100193_bib20","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1016\/S0021-9258(18)48191-4","article-title":"Relationship of the 90-kDa murine heat shock protein to the untransformed and transformed states of the L cell glucocorticoid receptor","volume":"262","author":"Sanchez","year":"1987","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib21","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/j.1460-2075.1985.tb04055.x","article-title":"The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein","volume":"4","author":"Catelli","year":"1985","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib22","article-title":"Steroid receptor interactions with heat shock protein and immunophilin chaperones*","volume":"18","author":"Pratt","year":"1997","journal-title":"Endocrine Rev"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib23","article-title":"hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures - PubMed","volume":"9","author":"Borkovich","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib24","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1038\/348166a0","article-title":"Reduced levels of hsp90 compromise steroid receptor action in vivo","volume":"348","author":"Picard","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cstres.2026.100193_bib25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1146\/annurev.bi.55.070186.005443","article-title":"The heat-shock response","volume":"55","author":"Lindquist","year":"1986","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cstres.2026.100193_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev.ge.22.120188.003215","article-title":"The heat-shock proteins","volume":"22","author":"Lindquist","year":"1988","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.cstres.2026.100193_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1083\/jcb.143.4.901","article-title":"Vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis","volume":"143","author":"Obermann","year":"1998","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/emboj\/17.16.4829","article-title":"ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo","volume":"17","author":"Panaretou","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.cstres.2026.100193_bib29","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1038\/358169a0","article-title":"Hsp90 chaperones protein folding in vitro","volume":"358","author":"Wiech","year":"1992","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.cstres.2026.100193_bib30","doi-asserted-by":"crossref","DOI":"10.1021\/bi00147a017","article-title":"A heat shock protein complex isolated from rabbit reticulocyte lysate can reconstitute a functional glucocorticoid receptor-Hsp90 complex - PubMed","volume":"31","author":"Scherrer","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.cstres.2026.100193_bib31","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1038\/nature749","article-title":"Hsp90 as a capacitor of phenotypic variation","volume":"417","author":"Queitsch","year":"2002","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ng1067","article-title":"Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution","volume":"33","author":"Sollars","year":"2002","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.01.023","article-title":"HSP90 shapes the consequences of human genetic variation - PubMed","volume":"168","author":"Karras","year":"2017","journal-title":"Cell"},{"issue":"6012","key":"10.1016\/j.cstres.2026.100193_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.1195487","article-title":"Hsp90 and environmental stress transform the adaptive value of natural genetic variation","volume":"330","author":"Jarosz","year":"2010","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.cstres.2026.100193_bib35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0813394106","article-title":"Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease - PubMed","volume":"106","author":"Cowen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5744","key":"10.1016\/j.cstres.2026.100193_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/science.1118370","article-title":"Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi - PubMed","volume":"309","author":"Cowen","year":"2005","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.2910510418","article-title":"Unusual expression and localization of heat-shock proteins in human tumor cells - PubMed","volume":"51","author":"Ferrarini","year":"1992","journal-title":"Int J Cancer"},{"issue":"6956","key":"10.1016\/j.cstres.2026.100193_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib40","first-page":"123","article-title":"17AAG: low target binding affinity and potent cell activity\u2014finding an explanation","volume":"2","author":"Chiosis","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2004.04.008","article-title":"Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90","volume":"11","author":"Vilenchik","year":"2004","journal-title":"Chem Biol"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 - PubMed","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/emboj\/21.10.2407","article-title":"Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy","volume":"21","author":"Citri","year":"2002","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib44","article-title":"Drugging the cancer chaperone HSP90","volume":"1113","author":"Paul","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/sj.embor.7400300","article-title":"Hsp90 restrains ErbB-2\/HER2 signalling by limiting heterodimer formation","volume":"5","author":"Citri","year":"2004","journal-title":"EMBO Rep"},{"key":"10.1016\/j.cstres.2026.100193_bib46","article-title":"V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors","volume":"103","author":"Grbovic","year":"2006"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib47","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer","volume":"3","author":"Sang","year":"2013","journal-title":"Cancer Discov"},{"issue":"14","key":"10.1016\/j.cstres.2026.100193_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-5428","article-title":"Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance","volume":"68","author":"Shimamura","year":"2008","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.cstres.2026.100193_bib49","article-title":"Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins","volume":"65","author":"Shimamura","year":"2005","journal-title":"Cancer Rese"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2007.09.007","article-title":"Non-oncogene addiction and the stress phenotype of cancer cells","volume":"130","author":"Solimini","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.cstres.2026.100193_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-06-4511","article-title":"High HSP90 expression is associated with decreased survival in breast cancer","volume":"67","author":"Pick","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11518-w","article-title":"The Hsp90 isoforms from S. cerevisiae differ in structure, function and client range","volume":"10","author":"Girstmair","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/nsmb.1565","article-title":"Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90","volume":"16","author":"Hessling","year":"2009","journal-title":"Nat Struct Mol Biol"},{"issue":"26","key":"10.1016\/j.cstres.2026.100193_bib56","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M800540200","article-title":"Conserved conformational changes in the ATPase cycle of human Hsp90 - PubMed","volume":"283","author":"Richter","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1074\/jbc.M115.702928","article-title":"Crowding activates heat shock protein 90","volume":"291","author":"Halpin","year":"2016","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2012.06.047","article-title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition - PubMed","volume":"150","author":"Taipale","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib59","doi-asserted-by":"crossref","DOI":"10.1017\/S0033583510000314","article-title":"Conformational dynamics of the molecular chaperone Hsp90 - PubMed","volume":"44","author":"Krukenberg","year":"2011","journal-title":"Quarterly Rev Biophys"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026044","article-title":"An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine - PubMed","volume":"6","author":"Echeverr\u00eda","year":"2011","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tcb.2018.10.004","article-title":"The Hsp70\u2013Hsp90 chaperone cascade in protein folding","volume":"29","author":"Luengo","year":"2019","journal-title":"Trends Cell Biol"},{"issue":"5-7","key":"10.1016\/j.cstres.2026.100193_bib62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1515\/hsz-2025-0112","article-title":"The evolution and diversification of the Hsp90 co-chaperone system","volume":"406","author":"Engler","year":"2025","journal-title":"Biol Chem"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s12192-013-0413-3","article-title":"Proteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasis","volume":"18","author":"Finka","year":"2013","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.cstres.2026.100193_bib64","first-page":"1243","article-title":"Chaperome networks\u2013redundancy and implications for cancer treatment","author":"Yan","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"52","key":"10.1016\/j.cstres.2026.100193_bib65","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.273.52.35194","article-title":"Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery - PubMed","volume":"273","author":"Chen","year":"1998","journal-title":"J Biol Chem"},{"issue":"7893","key":"10.1016\/j.cstres.2026.100193_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04252-1","article-title":"Structure of Hsp90-Hsp70-Hop-GR reveals the Hsp90 client-loading mechanism - PubMed","volume":"601","author":"Wang","year":"2022","journal-title":"Nature"},{"issue":"38","key":"10.1016\/j.cstres.2026.100193_bib67","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M406882200","article-title":"Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37","volume":"279","author":"Prince","year":"2004","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1097-2765(02)00785-2","article-title":"Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1","volume":"10","author":"Panaretou","year":"2002","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2005.11.085","article-title":"The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins - PubMed","volume":"356","author":"McLaughlin","year":"2006","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-023-01128-y","article-title":"Cryo-EM reveals how Hsp90 and FKBP immunophilins co-regulate the glucocorticoid receptor - PubMed","volume":"30","author":"Noddings","year":"2023","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cstres.2025.100118","article-title":"Hsp70 and Hsp90 post-translational modifications and translating the chaperone code","volume":"30","author":"Backe","year":"2025","journal-title":"Cell Stress Chaperones"},{"issue":"32","key":"10.1016\/j.cstres.2026.100193_bib72","doi-asserted-by":"crossref","first-page":"11099","DOI":"10.1074\/jbc.REV120.011833","article-title":"Post-translational modifications of Hsp90 and translating the chaperone code","volume":"295","author":"Backe","year":"2020","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib73","article-title":"Post-translational modifications of Hsp90 and their contributions to chaperone regulation","volume":"1823","author":"Mollapour","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2011.02.011","article-title":"Threonine 22 phosphorylation attenuates Hsp90 interaction with co-chaperones and affects its chaperone activity","volume":"41","author":"Mollapour","year":"2011","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2012.05.015","article-title":"Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine - PubMed","volume":"47","author":"Xu","year":"2012","journal-title":"Mol Cell"},{"key":"10.1016\/j.cstres.2026.100193_bib76","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.celrep.2015.12.084","article-title":"Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors","volume":"14","author":"Woodford","year":"2016","journal-title":"Cell Reports"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of Hsp90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2013.12.007","article-title":"Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors","volume":"53","author":"Mollapour","year":"2014","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib80","doi-asserted-by":"crossref","DOI":"10.1101\/gad.177758.111","article-title":"Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization","volume":"26","author":"Donlin","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.cstres.2026.100193_bib81","article-title":"A methylated lysine is a switch point for conformational communication in the chaperone Hsp90","volume":"11","author":"Rehn","year":"2020","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.cstres.2026.100193_bib82","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0407294102","article-title":"S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities","volume":"102","author":"Mart\u00ednez-Ruiz","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.cstres.2026.100193_bib83","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.91.18.8324","article-title":"Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation - PubMed","volume":"91","author":"Whitesell","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"47","key":"10.1016\/j.cstres.2026.100193_bib84","doi-asserted-by":"crossref","first-page":"37181","DOI":"10.1074\/jbc.M003701200","article-title":"The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone","volume":"275","author":"Marcu","year":"2000","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib85","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M512406200","article-title":"Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90 evidence that coumarin antibiotics disrupt Hsp90 dimerization","volume":"281","author":"Allan","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib86","doi-asserted-by":"crossref","unstructured":"Peng S, Woodruff J, Pathak PK, et al. Crystal structure of the middle and C-terminal domains of Hsp90\u03b1 labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target. urn:issn:2059-7983. 2022\u201304\u201308;78(5).","DOI":"10.1107\/S2059798322002261"},{"issue":"32","key":"10.1016\/j.cstres.2026.100193_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/anie.200900929","article-title":"Molecular mechanism of inhibition of the human protein complex Hsp90\u2013Cdc37, a kinome chaperone\u2013cochaperone, by triterpene celastrol","volume":"48","author":"Sreeramulu","year":"2009","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.cstres.2026.100193_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19783-w","article-title":"The Hsp70-Hsp90 co-chaperone Hop\/Stip1 shifts the proteostatic balance from folding towards degradation","volume":"11","author":"Bhattacharya","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib89","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.108.022004","article-title":"Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action - PubMed","volume":"36","author":"Guo","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.freeradbiomed.2010.03.001","article-title":"Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs - PubMed","volume":"48","author":"Samuni","year":"2010","journal-title":"Free Radical Biol Med"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib91","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib92","doi-asserted-by":"crossref","DOI":"10.1007\/BF00689048","article-title":"Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent - PubMed","volume":"36","author":"Supko","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.cstres.2026.100193_bib93","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","article-title":"HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab","volume":"17","author":"Modi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10.1016\/j.cstres.2026.100193_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study - PubMed","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.cstres.2026.100193_bib95","unstructured":"Schnur R.C., Corman M.L., Gallaschun R.J., et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. May 1, 2002."},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib96","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1379\/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2","article-title":"Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin","volume":"3","author":"Schulte","year":"1998","journal-title":"Cell Stress Chaperones"},{"issue":"22","key":"10.1016\/j.cstres.2026.100193_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/91.22.1940","article-title":"DT-diaphorase expression and tumor cell sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90","volume":"91","author":"Kelland","year":"1999","journal-title":"JNCI J Nat Cancer Inst"},{"issue":"21","key":"10.1016\/j.cstres.2026.100193_bib98","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-05-2029","article-title":"Formation of 17-Allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.cstres.2026.100193_bib99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0602650103","article-title":"A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues - PubMed","volume":"103","author":"Gooljarsingh","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"18","key":"10.1016\/j.cstres.2026.100193_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies - PubMed","volume":"23","author":"Banerji","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"34","key":"10.1016\/j.cstres.2026.100193_bib101","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(00)81588-3","article-title":"Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 Complex) that forms a stress-sensitive complex with HSF1","volume":"94","author":"Zou","year":"1998","journal-title":"Cell"},{"issue":"49","key":"10.1016\/j.cstres.2026.100193_bib103","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M105931200","article-title":"Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex","volume":"276","author":"Guo","year":"2001","journal-title":"J Biol Chem"},{"issue":"46","key":"10.1016\/j.cstres.2026.100193_bib104","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M509497200","article-title":"Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing bax translocation*","volume":"280","author":"Stankiewicz","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/S1074-5521(03)00075-9","article-title":"Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90","volume":"10","author":"Jez","year":"2003","journal-title":"Chem Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib106","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00280-004-0947-2","article-title":"Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models","volume":"56","author":"Smith","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cstres.2026.100193_bib107","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00280-004-0939-2","article-title":"vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative","volume":"56","author":"Hollingshead","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cstres.2026.100193_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00280-005-1000-9","article-title":"Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance","volume":"56","author":"Glaze","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"46","key":"10.1016\/j.cstres.2026.100193_bib109","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0608372103","article-title":"Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 - PubMed","volume":"103","author":"Sydor","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"10.1016\/j.cstres.2026.100193_bib110","article-title":"Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-Amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90","volume":"49","author":"Jie","year":"2006","journal-title":"J Med Chem"},{"issue":"33","key":"10.1016\/j.cstres.2026.100193_bib111","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.30.8338","article-title":"Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer - PubMed","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.cstres.2026.100193_bib112","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-0953","article-title":"A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas - PubMed","volume":"19","author":"Wagner","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib113","doi-asserted-by":"crossref","DOI":"10.2174\/1568009033481859","article-title":"Development of radicicol analogues - PubMed","volume":"3","author":"Soga","year":"2003","journal-title":"Curr Cancer Drug Targets"},{"issue":"15","key":"10.1016\/j.cstres.2026.100193_bib114","doi-asserted-by":"crossref","DOI":"10.2174\/156802609789895665","article-title":"Hsp90 inhibition with resorcyclic acid lactones (RALs) - PubMed","volume":"9","author":"Winssinger","year":"2009","journal-title":"Curr Top Med Chem"},{"issue":"17","key":"10.1016\/j.cstres.2026.100193_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.200900494","article-title":"Inhibition of HSP90 with pochoximes: SAR and structure-based insights - PubMed","volume":"10","author":"Barluenga","year":"2009","journal-title":"Chembiochem Eur J Chem Biol"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.cstres.2026.100193_bib117","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-3404","article-title":"First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors - PubMed","volume":"19","author":"Sessa","year":"2013","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cstres.2026.100193_bib118","article-title":"Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer - PubMed","volume":"15","author":"Williams","year":"2023","journal-title":"Therap Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib119","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-08-0758","article-title":"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90","volume":"8","author":"Lundgren","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cstres.2026.100193_bib121","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.ejca.2014.07.017","article-title":"Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours","volume":"50","author":"Infante","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2015.422","article-title":"Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies","volume":"114","author":"Yong","year":"2016","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/bjc.2017.302","article-title":"A phase I\/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma","volume":"117","author":"Cavenagh","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib124","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer - PubMed","volume":"3","author":"Sang","year":"2013","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.19.00816","article-title":"Randomized phase III Study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small-cell lung cancer (GALAXY-2)","volume":"38","author":"Pillai","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.cstres.2026.100193_bib126","doi-asserted-by":"crossref","DOI":"10.1021\/jm100060b","article-title":"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design - PubMed","volume":"53","author":"Woodhead","year":"2010","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib127","article-title":"Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial - PubMed","volume":"33","author":"Kurokawa","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"13","key":"10.1016\/j.cstres.2026.100193_bib128","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-022-01764-6","article-title":"Pimitespib: first approval - PubMed","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib129","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","article-title":"TAS-116, a highly selective inhibitor of heat shock protein 90\u03b1 and \u03b2, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models","volume":"14","author":"Ohkubo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cstres.2026.100193_bib130","first-page":"5","article-title":"TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-na\u00efve and imatinib-resistant gastrointestinal stromal tumours","volume":"122","author":"Saito","year":"2019","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib131","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/2326-6066.CIR-24-0713","article-title":"The HSP90 inhibitor pimitespib targets regulatory T cells in the tumor microenvironment","volume":"13","author":"Tsuge","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib132","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nrm.2017.73","article-title":"Regulation of heat shock transcription factors and their roles in physiology and disease","volume":"19","author":"Gomez-Pastor","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"10.1016\/j.cstres.2026.100193_bib133","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.274.24.17219","article-title":"Modulation of human heat shock factor trimerization by the linker domain *","volume":"274","author":"Liu","year":"1999","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib134","first-page":"19","article-title":"Direct activation of HSF1 by macromolecular crowding and misfolded proteins","volume":"4","author":"Simoncik","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.cstres.2026.100193_bib135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/nsmb.3149","article-title":"Structure of human heat-shock transcription factor 1 in complex with DNA","volume":"23","author":"Neudegger","year":"2016","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib136","article-title":"The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by hsp70","volume":"13","author":"Mosser","year":"1993","journal-title":"Mol Cellular Biol"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2021.10.004","article-title":"Molecular mechanisms of heat shock factor 1 regulation","volume":"47","author":"Kmiecik","year":"2022","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.cstres.2026.100193_bib138","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4020-6401-2_11","article-title":"Hsp70 and Hsp27 as pharmacological targets in apoptosis modulation for","author":"Brunet","year":"2007","journal-title":"Heat Shock Proteins Cancer"},{"issue":"22","key":"10.1016\/j.cstres.2026.100193_bib139","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-06-1629","article-title":"Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism","volume":"66","author":"McCollum","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib140","article-title":"HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers","volume":"150","author":"Mendillo Marc","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2014.05.045","article-title":"The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy - PubMed","volume":"158","author":"Scherz-Shouval","year":"2014","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib142","first-page":"2019","article-title":"HSP90: enabler of cancer adaptation","volume":"3","author":"Jaeger","year":"2019","journal-title":"Ann Rev Cancer Biol"},{"key":"10.1016\/j.cstres.2026.100193_bib143","article-title":"HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models","volume":"111","author":"Whitesell","year":"2014"},{"issue":"21","key":"10.1016\/j.cstres.2026.100193_bib144","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0596","article-title":"Rebalancing protein homeostasis enhances tumor antigen presentation - PubMed","volume":"25","author":"Jaeger","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.cstres.2026.100193_bib145","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-11-053728","article-title":"Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells","volume":"110","author":"Davenport","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib146","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-019-0158-7","article-title":"HSP90\/AXL\/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer - PubMed","volume":"8","author":"Yang","year":"2019","journal-title":"Oncogenesis"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib147","doi-asserted-by":"crossref","DOI":"10.1080\/15548627.2018.1434471","article-title":"HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC - PubMed","volume":"14","author":"Han","year":"2018","journal-title":"Autophagy"},{"issue":"7560","key":"10.1016\/j.cstres.2026.100193_bib148","doi-asserted-by":"crossref","DOI":"10.1038\/nature14430","article-title":"Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment - PubMed","volume":"523","author":"Alexandrova","year":"2015","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.cstres.2026.100193_bib149","article-title":"Combined EGFR\/MET or EGFR\/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET","volume":"72","author":"Lu","year":"2012","journal-title":"Cancer research"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib150","article-title":"Integrin \u03b1v\u03b23 induces HSP90 inhibitor resistance via FAK activation in KRAS-mutant non\u2013small cell lung cancer","volume":"54","author":"Yoon","year":"2021","journal-title":"Cancer Res Treatment Off J Korean Cancer Assoc"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib151","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2009.337","article-title":"Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth - PubMed","volume":"29","author":"Chandarlapaty","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib152","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5295-z","article-title":"Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer","volume":"19","author":"Mumin","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2008.380","article-title":"Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors - PubMed","volume":"28","author":"Smith","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib154","doi-asserted-by":"crossref","DOI":"10.1172\/JCI37613","article-title":"Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90 - PubMed","volume":"119","author":"Kang","year":"2009","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib155","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1200593","article-title":"Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells - PubMed","volume":"190","author":"Bae","year":"2013","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib156","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/jnci\/92.3.242","article-title":"Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins","volume":"92","author":"Marcu","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.cstres.2026.100193_bib157","doi-asserted-by":"crossref","DOI":"10.2174\/092986708786242895","article-title":"Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket - PubMed","volume":"15","author":"Donnelly","year":"2008","journal-title":"Curr Med Chem"},{"issue":"48","key":"10.1016\/j.cstres.2026.100193_bib158","doi-asserted-by":"crossref","DOI":"10.1021\/ja065793p","article-title":"Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90 - PubMed","volume":"128","author":"Burlison","year":"2006","journal-title":"J Am Chem Soc."},{"key":"10.1016\/j.cstres.2026.100193_bib159","first-page":"129","article-title":"Anticancer inhibitors of Hsp90 function: beyond the usual suspects - PubMed","author":"Garg","year":"2016","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.cstres.2026.100193_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2014.10.034","article-title":"Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors - PubMed","volume":"89","author":"Zhao","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib161","first-page":"6","article-title":"Design, Synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors","volume":"27","author":"Garg","year":"2014","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2016.11.030","article-title":"Blagg B. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors - PubMed","volume":"25","author":"Garg","year":"2017","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"10.1016\/j.cstres.2026.100193_bib163","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA118.002502","article-title":"Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32 - PubMed","volume":"294","author":"Chatterjee","year":"2019","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.cstres.2026.100193_bib164","doi-asserted-by":"crossref","DOI":"10.1039\/C8MD00151K","article-title":"Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain - PubMed","volume":"9","author":"Kumar Mv","year":"2018","journal-title":"Medchemcomm"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib165","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M112.427328","article-title":"Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis - PubMed","volume":"288","author":"Patwardhan","year":"2013","journal-title":"J Biol Chem"},{"issue":"51","key":"10.1016\/j.cstres.2026.100193_bib166","doi-asserted-by":"crossref","first-page":"35381","DOI":"10.1074\/jbc.M109.051532","article-title":"Characterization of celastrol to inhibit hsp90 and cdc37 interaction","volume":"284","author":"Zhang","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib167","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-79","article-title":"HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0\/G1 in thiol-containing agents reversible way - PubMed","volume":"9","author":"Peng","year":"2010","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib168","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.081018","article-title":"Celastrol Inhibits Hsp90 Chaperoning of Steroid Receptors by Inducing Fibrillization of the Co-chaperone p23","volume":"285","author":"Chadli","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib169","doi-asserted-by":"crossref","DOI":"10.1021\/ml900003t","article-title":"Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90 - PubMed","volume":"1","author":"Vasko","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib170","article-title":"A novel cyclic pentapeptide, H-10, inhibits B16 cancer cell growth and induces cell apoptosis - PubMed","volume":"8","author":"Zhang","year":"2014","journal-title":"Oncol Letts"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib171","article-title":"A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis - PubMed","volume":"15","author":"Wang","year":"2018","journal-title":"Oncol Letts"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib172","article-title":"Novel cyclic pentapeptide H-15 induces differentiation and inhibits proliferation in murine melanoma B16 cells - PubMed","volume":"11","author":"Liu","year":"2016","journal-title":"Oncol Letts"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib173","article-title":"Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells","volume":"32","author":"Mancang","year":"2013","journal-title":"Investig New Drugs"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib174","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bcp.2009.09.017","article-title":"Withaferin A targets heat shock protein 90 in pancreatic cancer cells","volume":"79","author":"Yu","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cstres.2026.100193_bib175","first-page":"E4801","article-title":"Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90\u03b2","volume":"113","author":"Yim","year":"2016"},{"issue":"5","key":"10.1016\/j.cstres.2026.100193_bib176","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12192-021-01222-4","article-title":"Gambogic acid and gambogenic acid induce a thiol-dependent heat shock response and disrupt the interaction between HSP90 and HSF1 or HSF2","volume":"26","author":"Pesonen","year":"2021","journal-title":"Cell Stress Chaperones"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102700","article-title":"Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment - PubMed","volume":"298","author":"Donahue","year":"2022","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100857","article-title":"Allosteric regulation of Hsp90\u03b1's activity by small molecules targeting the middle domain of the chaperone - PubMed","volume":"23","author":"Zhou","year":"2020","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108308","article-title":"Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer - PubMed","volume":"26","author":"Eisa","year":"2023","journal-title":"iScience"},{"issue":"51","key":"10.1016\/j.cstres.2026.100193_bib180","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl7295","article-title":"Client binding shifts the populations of dynamic Hsp90 conformations through an allosteric network","volume":"7","author":"Lopez","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.cstres.2026.100193_bib181","first-page":"181","article-title":"Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: a comprehensive review","author":"Liew","year":"2022","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.cstres.2026.100193_bib182","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.3390\/ijms25105468","article-title":"Plant-based HSP90 inhibitors in breast cancer models: a systematic review","volume":"25","author":"Zarguan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib183","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/biom12091166","article-title":"Cytosolic Hsp90 isoform-specific functions and clinical significance","volume":"12","author":"Maiti","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/S0163-7258(98)00013-8","article-title":"The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review","volume":"79","author":"Csermely","year":"1998","journal-title":"Pharmacol Therap"},{"issue":"20","key":"10.1016\/j.cstres.2026.100193_bib185","doi-asserted-by":"crossref","DOI":"10.7150\/thno.36505","article-title":"Inhibition of HSP90\u03b2 improves lipid disorders by promoting mature SREBPs degradation via the ubiquitin-proteasome system - PubMed","volume":"9","author":"Zheng","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.cstres.2026.100193_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02013-1","article-title":"Structure-guided design of an Hsp90\u03b2 N-terminal isoform-selective inhibitor","volume":"9","author":"Khandelwal","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib187","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.jmedchem.0c01700","article-title":"The development of Hsp90\u03b2-selective inhibitors to overcome detriments associated with pan-Hsp90 inhibition","volume":"64","author":"Mishra","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117925","article-title":"Optimization of an Hsp90\u03b2-selective inhibitor via exploration of the Hsp90 N-terminal ATP-binding pocket - PubMed","volume":"297","author":"Serwetnyk","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005045","article-title":"Frontiers | Hsp90\u03b2 inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors","volume":"13","author":"Rahmy","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cstres.2026.100193_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213488","article-title":"Integrative multi-omics analyses reveal mechanisms of resistance to Hsp90\u03b2-selective inhibition","volume":"17","author":"Mersich","year":"2025","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.cstres.2026.100193_bib191","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202015422","article-title":"Selective Inhibition of the Hsp90\u03b1 Isoform - PubMed","volume":"60","author":"Mishra","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib192","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.2c00327","article-title":"Structure-activity relationship study of tertiary alcohol Hsp90\u03b1-selective inhibitors with novel binding mode - PubMed","volume":"13","author":"Mishra","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib193","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.3c00265","article-title":"Synthesis and validation of the first cell-impermeable Hsp90\u03b1-selective inhibitors - PubMed","volume":"14","author":"Reynolds","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"30","key":"10.1016\/j.cstres.2026.100193_bib194","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M001476200","article-title":"Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. II. Ligand-mediated activation of GRP94 molecular chaperone and peptide binding activity - PubMed","volume":"275","author":"Wassenberg","year":"2000","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.cstres.2026.100193_bib195","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nchembio.1335","article-title":"Paralog-selective Hsp90 inhibitors define tumor-specific regulation of Her2","volume":"9","author":"Patel","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib196","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b00197","article-title":"Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94 - PubMed","volume":"58","author":"Patel","year":"2015","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib197","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.6b00747","article-title":"Transformation of the non-selective aminocyclohexanol-based Hsp90 inhibitor into a Grp94-seletive scaffold - PubMed","volume":"12","author":"Mishra","year":"2017","journal-title":"ACS Chem Biol"},{"issue":"62","key":"10.1016\/j.cstres.2026.100193_bib198","article-title":"Second generation Grp94-selective inhibitors provide opportunities for the inhibition of metastatic cancer","volume":"23","author":"Vincent","year":"2017","journal-title":"Chem Eur J"},{"issue":"13","key":"10.1016\/j.cstres.2026.100193_bib199","doi-asserted-by":"crossref","DOI":"10.1021\/ja511893n","article-title":"Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1 - PubMed","volume":"137","author":"Lee","year":"2015","journal-title":"J Am Chem Soc."},{"key":"10.1016\/j.cstres.2026.100193_bib200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00058","article-title":"The chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells - PubMed","volume":"7","author":"Masgras","year":"2017","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2013.12.023","article-title":"Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism - PubMed","volume":"53","author":"Lavery","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.cstres.2026.100193_bib202","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25235","article-title":"Symmetry broken and rebroken during the ATP hydrolysis cycle of the mitochondrial Hsp90 TRAP1 - PubMed","volume":"6","author":"Elnatan","year":"2017","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib203","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14082-5","article-title":"The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction - PubMed","volume":"11","author":"Inda","year":"2020","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.cstres.2026.100193_bib204","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.cstres.2026.100193_bib205","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3704","article-title":"First-in-human trial of epichaperome-targeted PET in patients with cancer - PubMed","volume":"26","author":"Dunphy","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib206","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00273","article-title":"Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus Nab-Paclitaxel in HER2-negative metastatic breast cancer - PubMed","volume":"4","author":"Jhaveri","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cstres.2026.100193_bib207","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1038\/s41467-021-24821-2","article-title":"Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system","volume":"12","author":"Bolaender","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib208","article-title":"Safety, tolerability and pharmacokinetics of icapamespib, a selective epichaperome inhibitor, in healthy adults - PubMed","volume":"9","author":"Silverman","year":"2022","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"10.1016\/j.cstres.2026.100193_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114013","article-title":"Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer - PubMed","volume":"228","author":"Liu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115690","article-title":"Discovery of X10g as a selective PROTAC degrader of Hsp90\u03b1 protein for treating breast cancer - PubMed","volume":"260","author":"Jiang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib211","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1219883","article-title":"Development of the first geldanamycin-based HSP90 degraders - PubMed","volume":"11","author":"Wurnig","year":"2023","journal-title":"Front Chem"},{"key":"10.1016\/j.cstres.2026.100193_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116572","article-title":"Novel Hsp90-targeting PROTACs: enhanced synergy with cisplatin in combination therapy of cervical cancer - PubMed","volume":"275","author":"Liang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"18","key":"10.1016\/j.cstres.2026.100193_bib213","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c01518","article-title":"Heat shock protein 90 interactome-mediated proteolysis targeting chimera (HIM-PROTAC) degrading glutathione peroxidase 4 to trigger ferroptosis - PubMed","volume":"67","author":"Dong","year":"2024","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.cstres.2026.100193_bib214","first-page":"68","article-title":"HSP90 mediates targeted degradation of nonclient protein PARP1 for breast cancer treatment","volume":"26","author":"Liu","year":"2025","journal-title":"J Med Chem. September"},{"key":"10.1016\/j.cstres.2026.100193_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-026-02682-w","article-title":"Development of a chaperone-mediated protein degrader targeting ERK5 that efficaciously reduces tumor growth","volume":"24","author":"Yang","year":"2026","journal-title":"Cell Commun Signal"},{"issue":"9","key":"10.1016\/j.cstres.2026.100193_bib216","first-page":"2139","article-title":"Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol1","volume":"63","author":"Solit","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib217","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-1570","article-title":"Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel - PubMed","volume":"68","author":"Sawai","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib218","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-011-9790-6","article-title":"Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models","volume":"30","author":"Proia","year":"2012","journal-title":"Investig New Drugs"},{"issue":"3","key":"10.1016\/j.cstres.2026.100193_bib219","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-009-9381-y","article-title":"Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and\/or cisplatin in patients with refractory solid tumors","volume":"29","author":"Hubbard","year":"2010","journal-title":"Investig New Drugs"},{"issue":"18","key":"10.1016\/j.cstres.2026.100193_bib220","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-1306","article-title":"Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural mesothelioma (MESO-02): a phase Ib trial - PubMed","volume":"26","author":"Fennell","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cstres.2026.100193_bib221","first-page":"162","article-title":"Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers - PubMed","author":"Gutierrez","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"4","key":"10.1016\/j.cstres.2026.100193_bib222","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib223","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2011.08664.x","article-title":"Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1\/2 study","volume":"153","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.cstres.2026.100193_bib224","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.29339","article-title":"Phase 1\/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma - PubMed","volume":"121","author":"Seggewiss-Bernhardt","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.cstres.2026.100193_bib225","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells - PubMed","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib226","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-017-0879-5","article-title":"A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer - PubMed","volume":"19","author":"Jhaveri","year":"2017","journal-title":"Breast Cancer Res BCR"},{"issue":"25","key":"10.1016\/j.cstres.2026.100193_bib227","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8974","article-title":"Phase 1B\/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen - PubMed","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2021.05.001","article-title":"Erlotinib and onalespib lactate focused on EGFR Exon 20 insertion non-small cell lung cancer (NSCLC): a California Cancer Consortium Phase I\/II Trial (NCI 9878) - PubMed","volume":"22","author":"Riess","year":"2021","journal-title":"Clinical Lung Cancer"},{"issue":"15","key":"10.1016\/j.cstres.2026.100193_bib229","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-3212","article-title":"Pharmacodynamic and clinical results from a phase I\/II study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer - PubMed","volume":"25","author":"Slovin","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"7","key":"10.1016\/j.cstres.2026.100193_bib230","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours","volume":"126","author":"Konstantinopoulos","year":"2022","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.cstres.2026.100193_bib231","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-15-0057","article-title":"Targeting heat-shock protein 90 (HSP90) as a complementary strategy to immune checkpoint blockade for cancer therapy","volume":"3","author":"Proia","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"10.1016\/j.cstres.2026.100193_bib232","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0596","article-title":"Rebalancing protein homeostasis enhances tumor antigen presentation","volume":"25","author":"Jaeger","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cstres.2026.100193_bib233","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chembiol.2020.10.005","article-title":"HSP90 inhibition enhances cancer immunotherapy by modulating the surface expression of multiple immune checkpoint proteins","volume":"28","author":"Zavareh","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib234","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41467-017-00449-z","article-title":"HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes","volume":"8","author":"Mbofung","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cstres.2026.100193_bib235","first-page":"13","article-title":"Hsp90\u03b2 inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors","author":"Rahmy","year":"2022","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.cstres.2026.100193_bib236","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-21-1929","article-title":"TAS-116 (Pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: an open-label, dose-finding, and expansion phase Ib trial (EPOC1704)","volume":"27","author":"Kawazoe","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cstres.2026.100193_bib237","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2475620","article-title":"XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib\/II clinical trial","volume":"14","author":"Phillips","year":"2025","journal-title":"Oncoimmunology"}],"container-title":["Cell Stress and Chaperones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814526000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1355814526000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:14:05Z","timestamp":1789384445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1355814526000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":237,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1355814526000490"],"URL":"https:\/\/doi.org\/10.1016\/j.cstres.2026.100193","relation":{},"ISSN":["1355-8145"],"issn-type":[{"value":"1355-8145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Hsp90 targeting: From stress biology to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Cell Stress and Chaperones","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cstres.2026.100193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Cell Stress Society International.","name":"copyright","label":"Copyright"}],"article-number":"100193"}}